Background: Anti-tumor necrosis factor a (anti-TNF-a) treatments are widely used in patients with rheumatoid arthritis (RA); however, the increased risk of infections is one of the most important side effects of anti-TNF-a agents. This study evaluated the differences between monoclonal antibodies and the soluble receptor for infections in patients with RA by direct comparison of observation studies.
INTRODUCTION
Anti-tumor necrosis factor a (anti-TNF-a) treatment, whose effectiveness has been demonstrated by a large scale of clinic trails, 3, 31 has been widely used in patients with rheumatoid arthritis (RA) who inadequately respond to non-biologic disease-modifying anti-rheumatic drugs (nb-DMARDs). 16, 26 Despite its superior clinical efficacy, there have been concerns that anti-TNF-a might lead to an increased risk of infections, because TNF-a plays an important role in host defense. 4, 5 This question cannot be fully addressed by randomized controlled trials (RCTs) because of their limited duration and sample size. Former observation studies revealed a mild increase compared with nbDMARDs and also showed a trend that monoclonal antibodies (infliximab [INF] , adalimumab [ADA]) were more likely to be associated with infections compared to soluble receptors (etanercept [ETA]). 6, 15 A Cochrane review (2011) also revealed a higher risk of infliximab for adverse events by conducting an indirect comparison of controlled trials and open-label extension studies. 27 However, it neither included observational studies nor focused on RA. Till now no randomized trial comparing these agents has been reported, while observational studies, especially the long-term ones, can provide reliable risks of infection in daily practice.
Therefore this meta-analysis is undertaken to evaluate the differences between monoclonal antibodies and soluble receptors for infections in patients with RA by direct comparison of observation studies.
METHODS

Search strategy
We conducted a primary search in MEDLINE, EMBASE and Cochrane Library in March 2014 and an up-to-date search was conducted in August 2014 using the following key words: 'Rheumatoidarthritis','biologics', 'TNFRFc fusion protein', 'anti-TNF, 'monoclonal antibodies', 'soluble receptors', 'infliximab', 'adalimumab', 'etanercept', 'infection', 'tuberculosis' with no limit used. We also checked the citation from selected articles and related meta-analyses.
Selection and outcomes
Articles were included only if they met all the following criteria:
1 RCT or prospective cohort studies 2 with participants of patients with RA 3 involving treatment with soluble receptors (ETA) or at least one of monoclonal antibodies (INF, ADA) and 4 reporting adverse events of any infections.
Quality assessment
Studies were evaluated by two independent reviewers using the Newcastle-Ottawa Scale (NOS), which scores the quality of studies in a scale of 0-9. And only those articles with NOS of 6 or greater were included.
Data extraction
For each eligible study, the following information was extracted: (i) first author's name and year of publication; (ii) biologic agent; (iii) number of patients; (iv) age; (v) disease duration; (vi) Disease Activity Score of 28 joints (DAS28); (vii) corticosteroids; and (viii) previous disease-modifying antirheumatic drugs (DMARDs). Our primary outcome was serious infections defined as life-threatening, requiring hospitalization and/or intravenous antibiotic therapy, or leading to significant disability/death. Our secondary outcomes were tuberculosis as well as other forms of infections. All the relevant data were extracted by two reviewers independently in accordance with a pre-established process.
Statistical analysis
Analysis of the risk ratio (RR) was performed by a fixed or random effects model according to their heterogeneity which was determined by the I 2 statistic: I 2 > 50% was considered substantial heterogeneity and the random effects model was used, while if I 2 < 50%, the fixed effects model was used. Results with P-values < 0.10 were considered statistically significant. The publication bias was represented by funnel plots. All these processes were conducted by Cochrane Collaboration Review Manager 5.0 software.
RESULTS
Study characteristics
Six hundred and nine articles were retrieved at first. After evaluating abstracts or full texts, 12 articles were finally included in this meta-analysis (shown in Fig. 1 ). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The NOS of all these included studies were 6 or higher with a mean of 7. The characteristics of the included studies are shown in Table 1 . A total of 24 656 patients were involved, 15 189 of which were treated with monoclonal antibodies and 9467 of which were treated with soluble receptors. The included articles were quite homogeneous in terms of patient characteristics such as age, disease duration and DAS28. However, they were quite different in concomitant therapy of corticosteroid, which in four studies were higher than 50%, in five were lower than 50% and in three were unknown. So a subgroup analysis was considered as appropriate.
Serious infections
A total of eight studies reported the difference of serious infections risk in mono-antibodies and soluble receptor, in which three compared ETA with INF, one compared ETA with ADA and the other four compared ETA with both. Taking ADA and INF as a whole, the pooled analysis showed that patients treated with ETA had a lower incidence rate (RR = 0.63 [0.40-0.97] P = 0.04); however, the heterogeneity was high (I 2 = 85%). So subgroup analysis of ADA and INF was conducted. Compared with ADA, the result was similar (RR = 0.69 [0.49-0.96] P = 0.03 I 2 = 52%), while in comparison of ETA and INF, the result was not statistically significant and the heterogeneity was still high (RR = 0.63 [0.36-1.09] P = 0.10 I 2 = 93%). However, after sensitivity analysis of the study of Sakai et al., 21 the result became significant (P = 0.05).
We also conducted a subgroup analysis according to the concomitant therapy of corticosteroid. In the subgroup with therapy of corticosteroid higher than 50%, there was no significant difference between soluble receptors and monoclonal antibodies, while in the subgroup lower than 50%, the difference was significant. However, its heterogeneity was high (shown in Fig. 2 ).
Tuberculosis
The pooled analysis of six studies showed that the soluble receptor ETA had a lower risk whether we took mono-antibodies as a whole (shown in Fig. 3 
General infections
General infections were defined as all kinds of infections regardless of their responsible micro-organisms and severity. And the analyses showed that ETA had a lower risk compared with mono-antibodies and its heterogeneity was high (shown in Fig. 4) , and a sensitivity analysis of studies with a sample size < 400 still 
Publication bias
Funnel plot for serious infections was asymmetric. So publication bias might exist. However, there was no evidence of publication bias for tuberculosis in which the funnel plot was symmetric (shown in Fig. 5 ).
DISCUSSION
In this meta-analysis, we conducted direct comparison of data from observational studies. We found that for serious infections, the soluble receptor ETA was safer In order to reduce bias, we only included prospective cohort studies. Our result was also consistent with some retrospective ones. 14 No significant difference was found between ADA and ETA. Curtis et al. observed that after initiation of anti-TNF therapy, the incidence of serious infections increased during the first 6 months compared to those who just received methotrexate, and it was only significant among patients exposed to INF. This risk decreased and became insignificant after the first 6 months due to dropouts of patients who are highly susceptible to infection. 7 In contrast to out result, the data from the LORHEN registry reported by Favalli et al. showed that compared with ETA, INF or ADA were not associated with a higher risk of serious infections (aHR 1.48 [95% CI, 0.70-3.14] P = 0.304 and aHR 1.73 [95% CI, 0.77-3.87] P = 0.182, respectively). 10 However, we have to notice that due to the underestimation of infections that might not have been fully reported, the overall rate of serious infections in this retrospective study was significantly lower than those reported in other prospective ones. 8, 17, 22 Further evidence from a Cochrane meta-analysis partially also supports our result. 27 Singh et al. compared the adverse effects of nine biologics to evaluate their safety. They found anti-TNF biologics have significantly higher rates of adverse events than non-TNF biologics. INF and ADA as the important monoclonal antibodies targeting the TNF receptors were associated with statistically significantly higher rates of total adverse events compared with placebo treatment, and INF was associated with a significantly higher rate of withdrawals due to adverse events, where ETA was not. However, as to serious infection, neither ADA, INF nor ETA increased the incidence significantly. However, this meta-analysis only conducted an indirect comparison of randomized controlled trials and no data from head-to-head comparisons of observational studies were included, and then across a variety of conditions, not just focusing on RA. As to tuberculosis in patients taking anti-TNF agents, our direct comparison showed the soluble receptor has a lower risk than monoclonal antibodies. This Cochrane meta-analysis did not reveal any consistent results about tuberculosis since the models did not converge for tuberculosis reactivation.
The differences between INF, ADA and ETA for the risk of increased infections might be explained by their different structures and modes of action. 30 INF is a humanized mouse monoclonal antibody, while ADA is a fully human monoclonal antibody. 20 These monoantibodies can bind to membrane-bound TNF as well as soluble TNF (both active and inactive forms), 23 and then form fixed complement, lysing these TNFexpressed cells and reducing host immune response. 24 However, ETA, a soluble TNF receptor fusion protein, is more likely to bind to active soluble TNF and tends to form relatively unstable complexes, allowing dissociation of TNF. 2 Although our study revealed a lower risk of infections for ETA compared with INF and ADA, caution must be taken when interpreting it due to the following limitations.
First, our meta-analysis only included published articles. Thus unpublished studies with negative results may add to the bias. The funnel plot also indicated this possibility. Meanwhile it is also possible that we did not retrieve all the published ones. The study design and the technique of quality rating observational studies may be simplistic and restrained, as with long-term follow-up deviation. Second, the heterogeneities were high, especially for serious infections and general infections and this could not be explained by subgroup analysis of different types of mono-antibodies or the concomitant therapy of corticosteroid, because infections are influenced by a variety of factors such as study designs and clinical features. Further, these differences did exist in our included studies. For example, the studies had different durations of follow-up and definitions of risk window after anti-TNF agents withdrawal or switch. It is possible that clinicians were less likely to prescribe anti-TNF therapy to patients who were perceived to have the highest risk of infection. They also differed in clinical features like concomitant therapies, which is a potential factor influencing the infection risks. Third, since most RCT studies are from developed countries and regions, this study's findings may not be generalizable to cohorts of other ethnicities or in regions where the background rates of infection differ, such as the high incidence of tuberculosis in China.
While this observational design has the above limitations, the data presented here reflect real-world experience of different anti-TNF agent therapy in RA, and thus it has clinical significance.
CONCLUSION
The soluble receptor has a lower risk for tuberculosis or general infections compared with mono-antibodies. However, for serious infections, no certain conclusion could be drawn due to the high heterogeneity and possibility of publication bias. Thus more well-designed long-term studies are needed.
